COMP <GO>
PEN vs GMED // ALTMAN Z-SCORE & DEBT/EQUITY
Penumbra Inc. (NYSE) VS. Globus Medical Inc. (NYSE) • 15-METRIC TALLY: PEN 4
— GMED 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: PEN
LAST: $321.97 (+1.15%) • MKT CAP: $12.68B
balance-sheet
21.05
LAST: $82.91 (+2.03%) • MKT CAP: $11.13B
balance-sheet
10.74
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PEN VS. GMED)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PEN | GMED | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.10% | 67.40% | -0.30 | GMED | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.60% | 8.70% | +1.90 | PEN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 52.0x | 17.6x | +34.40 | GMED | /valuation <GO> |
| Free Cash Flow Yield | 1.38% | 5.29% | -3.91 | GMED | /fcf-yield <GO> |
| Operating Margin | 13.50% | 16.30% | -2.80 | GMED | /operating-margins <GO> |
| Net Profit Margin | 12.70% | 18.30% | -5.60 | GMED | /net-margins <GO> |
| Revenue Growth (YoY) | 17.50% | 16.70% | +0.80 | PEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 21.05 | 10.74 | +10.31 | PEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.9 | 59.8 | -7.90 | GMED | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.07 | -0.16 | GMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 60.0x | 17.4x | +42.60 | GMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $12.68B | $11.13B | $1.55B | PEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PEN REV | GMED REV | PEN GROSS % | GMED GROSS % | PEN FCF | GMED FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.40B | $2.94B | 67.1% | 67.4% | $174.9M | $588.8M |
| FY 2024 | $1.19B | $2.52B | 63.2% | 58.9% | $147.3M | $405.2M |
| FY 2023 | $1.06B | $1.57B | — | — | $49.7M | $172.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PEN // BETA 0.91
GMED // BETA 1.07